CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
Cardiobase

Search results for "LCZ696"

The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and imp ...


LCZ696 has shown to be superior to Ace inhibitor Enalapril ( Enapren ) on key endpoints in the largest heart failure study ever done. In PARADIGM-HF patients with heart failure with reduced ejection f ...


New data on investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction ( HFrEF ) have shown it has the potential to change the course of the disease for patients. ...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart ...


The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New ...


A 8-week, multicenter, open-label study has assessed the safety and efficacy of LCZ696 ( Entresto ), a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension ...


The effect of LCZ696 on blood pressure was evaluated in patients with heart failure with preserved ejection fraction ( HFpEF ) in the PARAMOUNT ( Prospective comparison of ARNI with ARB on Management ...


Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk ...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial has demonstrated that a new angiotensin receptor antagonist - ...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared with Enalapril in patients with chroni ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published in European Heart Journal and the European Journal of Heart Failure, ...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac death and hospitalization due to heart failure. Now, researchers from Kuma ...